Neurotype
Minneapolis, MN
Medical device focused on treating brain circuits that underlie drug craving caused by environmental triggers for drug use addiction healthcare. People in recovery are constantly reminded of drug use by environmental cues (people, places, things linked to prior drug use), remaining a persistent risk for relapse, overdoses, and diminished life quality. The NeuromarkR platform (headset+software) measures brain signatures of drug craving not currently addressed in gold standard addiction healthcare. NeuromarkR enables targeted interventions to address triggers for craving by tailored psychotherapy that uses Cognitive Behavioral Therapy (CBT) and Mindfulness-Based Treatment (MBT) strategies.
neurotype.ioCompany Details
Founded
- 2019
Employees
- Between 5 - 10 employees
Raised
- $1,166,946
Headquarters Location
- Minneapolis, MN
Public
- No
Acquired
- No
CEO
- Scott Burwell
Founders
- Scott Burwell
Company Collections
These are collections Neurotype is a part of. Click on the collection name to view similar companies.